Relugolix vs leuprolide to improve prostate cancer quality of life
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study compares two medicines that lower testosterone—relugolix tablets versus leuprolide injections—to see which better improves quality of life. It’s for people with prostate cancer who are starting hormone treatment and have not used similar testosterone-lowering drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer confirmed by a biopsy called “prostate adenocarcinoma.”
- You must be able to start testosterone-lowering treatment for about 6 months using either leuprolide injections or relugolix tablets.
- You cannot have taken a GnRH medicine (either agonist or antagonist) before.
- Your baseline testosterone must be above 200 ng/mL before hormone treatment starts.
- You must be healthy enough for study meds: good blood counts and acceptable liver and kidney test results.
- You must be able to take pills (if you’re assigned relugolix), and be able to consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.